OM:SOBIBiotechs
Does Health Canada’s EMPAVELI Approval in C3G and IC-MPGN Change The Bull Case For Sobi (OM:SOBI)?
Swedish Orphan Biovitrum (Sobi) and partner Apellis Pharmaceuticals have received Health Canada approval for EMPAVELI (pegcetacoplan) to treat rare kidney diseases C3 glomerulopathy and primary IC-MPGN in patients aged 12 and older, based on Phase 3 VALIANT data showing reduced proteinuria, stabilized kidney function, and clearance of C3 deposits.
This decision extends EMPAVELI’s nephrology footprint beyond the US and EU into Canada, adding another rare-disease indication to Sobi’s portfolio...